Become a Creator today!Start creating today - Share your story with the world!
Start for free
00:00:00
00:00:01
Ep. 21 Emily Fang on Authentically Understanding a Global Audience
0 Plays2 seconds ago
We sit down with Emily Fang, CEO of InFocus Therapeutics, to discuss her global BD career, partnerships in biotech, and the state of RNA-targeting small molecules. Emily describes the deep understanding she builds with partners and investors around the world.
Recommended
Transcript
Introduction of MightySpark Communications
00:00:00
Speaker
Hi everyone and welcome Sparktime. I'm Dani Stoltzfus and I'm Will Riedel of MightySpark Communications. Our mission is to use scientific innovation to drive transformative change.
00:00:11
Speaker
We believe that compelling storytelling is the most effective tool we have in our arsenal to motivate and inspire audiences to invest themselves in audacious goals. We are scientists by training, storytellers by experience and entrepreneurs by nature. Let's get started.
Emily Fong's Career Journey
00:00:29
Speaker
So today we're excited to share this episode with Emily Fong, the CEO of InFocus Therapeutics. InFocus is building a platform and pipeline of small molecules targeting RNA for multiple indications. And actually, Emily brought a very unique perspective to the discussion because she spent most of her career in business development in the CRO space.
00:00:50
Speaker
So this has taken her across the globe and through a career that looks differentiated from many scientists, founders. So we really value the insights that she shared with us. Yeah, I mean, not only scientists, founders, but traditional biotech founders, too. It's a very different path. And and i mean, that was one of the first things I really enjoyed about listening to Emily speak was hearing how her background has influenced what she's doing now. And specifically, you know, all that global training that she's received and how that really helps her to listen to her audience.
00:01:21
Speaker
Because, of of course, when you hear your audience, you really understand them. And Emily appears to have mastered this aspect of communication with her international negotiations.
InFocus Therapeutics' Strategic Plans
00:01:30
Speaker
And I believe her when she says that the her in the trenches experience is irreplaceable.
00:01:36
Speaker
On the topic of her CRO experience, she's taken some interesting lessons from that world that have enabled her to really cost effectively advance InFocus's platform um from their materials. It's obvious that they've done so much with the funding that they have, but as Emily describes, it's really going to be an exciting year for InFocus as they continue to raise capital and advance their platform and pipeline assets. Yeah, and some of the other highlights from today's discussion include Emily talking about her decision-making infrastructure, which is really helping her to strategically push the idFocus platform forward.
Challenges in Investor Communication
00:02:11
Speaker
um She talks about how communicating a platform sometimes that feels too far ahead of its field can be challenging, and she speaks about how she thinks about that when engaging investors from across the globe.
00:02:22
Speaker
Let's get into it. Emily Fong is the president and CEO of InFocus Therapeutics, a company advancing their novel discovery platform to identify new RNA drugs at unmatched throughput and scale.
00:02:35
Speaker
Emily has more than 12 years of diverse experience in integrated drug discovery and development across therapeutic modalities and indications, including oncology, neuroscience, immunology, genetic diseases, from startups to multinational organizations.
00:02:50
Speaker
Her scientific background is in medicinal chemistry, molecular biology, and cell biology. Emily specializes in international business development, collaborating with biotech and pharma companies with frontline experience in building strategic and commercial partnerships from the ground up, leading to several multimillion pluriannual deals and contracts with companies in the USA, Canada, Japan, France, Belgium, Germany, and Switzerland.
00:03:13
Speaker
Emily is formerly the Deputy Head of Business Development at OncoDesign, a French biotech and contract research organization, and had been in director-level management positions in established global organizations.
00:03:26
Speaker
She's a current board member at GenCensor, a French biotech deep tech company in bioproduction. Hey, Emily, thanks so much for joining us on the podcast today. How are you? I'm great. Thank you. Thanks so much, Will. Thanks, Danny, for the invitation.
00:03:39
Speaker
Yeah, absolutely. I'm going to dive right in and talk about your career because you've been ah all across the world. You've been to Paris, you've been in Boston, China and beyond. And I can imagine that building partnerships across such vastly different business and cultural landscapes must have been really challenging.
00:03:56
Speaker
Do you think that working in so many global hubs has shaped the way you lead, negotiate and build companies?
International Experience and Leadership
00:04:04
Speaker
Are there any specific lessons from these experiences that give you an edge where others may struggle? Yeah, thanks, Dani. Challenging, but very very interesting. um I would say that, again, with the benefit of hindsight, um my personal and professional lives have revolved around, and I really take away um this global perspective as, as you said, an edge of value that i lean upon and also I hope to contribute back.
00:04:32
Speaker
And I think when you talk about culture, right, so I think that's the first thing that we we always talk about when we speak about different groups of people, different countries. And what that really means is people's, like the true understanding of people's intentions, right, motivations, what drives them, what they truly care about. Because ultimately, when you're trying to lead or to negotiate or to build a relationship, a partnership,
00:04:56
Speaker
is when you you try to um engender some kind of action. But you want the action, if it's about leadership, you want the action to be a self-motivated, um or if you're negotiating, well you well ideally, our interests align.
00:05:11
Speaker
So to really understand that, you you have to have an authentic, thorough understanding that's beyond the superficial, or else you can't achieve this as the at at the highest level.
00:05:22
Speaker
So I suppose the edge of what it gives me is that I've actually physically lived you know actual years and in these environments. So that's there's no um no substitute for that. You have to spend the days and the hours and the sweat and the tears on the field. There's no shortcuts.
00:05:38
Speaker
So I do emphasize, whether it's with the team members, colleagues, um friends, that you have to be on the front line, you have to be in the trenches, you have to talk to the people.
00:05:50
Speaker
You have to work with them. And it's it's you know beyond what you see on TV, what you read in books, that perhaps stereotypes of Americans, Europeans, Asians, and all that kinds of things. You have to spend real time with your partners so that there's that nuance and that appreciation.
00:06:05
Speaker
Because i think it's what Will said in the beginning, if you want to truly communicate and to lead, to negotiate, and to resolve problems, there has to be um actually deep understanding of your audience, your counterparts.
00:06:19
Speaker
or your potential partners. So I think that's the biggest thing that's important to me.
00:06:26
Speaker
Yeah, i really i really feel that so similar about those things with you, Emily. I mean, my background is not nearly as diverse as yours, having primarily lived most of my career in Australia or the US, but even still, those two cultures are drastically different in terms of how business is done. And I think that, you know, I've always thought I have a unique perspective so from having lived and done the sweat and the tears in both countries. So it's really, really validating and cool to hear that you've had that same experience and how it really does give you an edge in terms of building and leading teams.
00:07:03
Speaker
I have good examples of this. So I've worked for um a primarily French CRO for some time, and one of their um longest and most important partners are Japanese pharma companies.
00:07:14
Speaker
So I've been in these meetings where the the English spoken is English, um but you can see that there's sometimes a misalignment in understanding. So when ah in my younger self, at this moment realized, it's not the translation of the language.
00:07:29
Speaker
It's the intention that's behind. So I completely understand what my French colleague trying to convey. And I can see that what what the Japanese pharma partner is thinking about, but they're not clicking. So my job there is to kind of ah bring this person a couple of steps here. And then then they find and there's there's that magical moment where you find there's alignment and everybody, you know, speaking a couple of words and and they're on the same page. And that's really nice. So it's a lovely experiences all around. Yes, very cool.
00:07:58
Speaker
Right. it It sounds like you spent so much time knowing your audience, which is something that that we're always telling clients is is know your audience and and speak to that audience. And so you've been in that position so many times, a lot of it driving business development, as you said, in the ah
Unique Insights from CRO Background
00:08:15
Speaker
CRO space. and But now, Emily, of course, you're leading in focus, a biotech company, which is focused on ah RNA targeting small molecules. So I'm kind of curious from your CRO experiences in the CRO world, what did that teach you um that most therapeutic biotech leaders are completely overlooking?
00:08:35
Speaker
Yeah, and there's a common thread from what we're talking about. this Again, there's the stereotypes. I remember coming out of my PhD, I didn't know about that this segment of the industry exists as CROs.
00:08:47
Speaker
And then um since kind of accidentally, serendipitously, being in that in those companies, um there's a stereotype that they're considered as vendors, you know ah service providers, right? Yes.
00:08:59
Speaker
And then I was in business development that in that sense that so I was a sales but in in a a salesperson for a long time. and And when you're young, you think, oh, I'm on the B side of the power dynamics or the negotiation table.
00:09:10
Speaker
But again, with maturity and now for over a decade, that's I realized that's an incredibly incredibly valuable experience. um It gave me the opportunity to interface, to collaborate with really countless large small large pharma companies, small biotech companies from all over the world.
00:09:27
Speaker
So I've been, ah you know, in a a contrary to ah people that have been in only biotechs or only pharmas who work on very specific projects for a long period of time, I was able to be on hundreds and hundreds of projects, you know, from just talking about it, um ah conceptualizing it, no sort of know what's at stake through that process, how to plan, execute it how to...
00:09:50
Speaker
convince the stakeholders from my clients to help my clients ah put the science together in a way that align with their business strategy and with their inflection points, which as you can imagine, serve me tremendously right now.
00:10:01
Speaker
um Of course, give me the the the network at the moment and the social capital that really money can't buy. And I'm really heavily leaning on that right now. There are a lot work that I'm able to get done by reputable CROs that's from my friends that I've worked for a long time.
00:10:19
Speaker
But i I want to add on the last point, it's it's important because it taught me respect, right? So how to respect that people we think are suppliers or vendors and these relationships, they are, um not because because i've I've been on the other side.
00:10:33
Speaker
So how to build these relationships with ah collaborators and that's very effective two-way relationship and that's ultimately benefiting the biotech itself. So I think that's the difference in perspective, definitely that I have.
00:10:46
Speaker
Yeah, that's really insightful. And, you know, having been in biotech and working with quote-unquote vendors, um I learned as well that, you know, that building those relationships with those people and getting that that trust established is so critical to actually executing any of your goals specifically.
00:11:07
Speaker
because, you know, when timelines are tight and budgets are constrained, you know that you're going to have to call that person say, hey look, can you help me do this, that, or the other thing really quickly, really cheaply, really fast, whatever the pressure is. And if you haven't invested in them as a partner and have seen them as solely a vendor, they're very unlikely to come to the party and help you and It's really cool to hear you speak to the value of that as well. And um I 100% agree that that's very different perspective that you're bringing. And I can only see that that would greatly serve you at this point in the stage of development that InFocus is at.
Success Factors in RNA Targeting
00:11:48
Speaker
Yes. All right, I want to switch to something a little tougher to talk about, and that's the ah RNA targeting space because we've spoken to some investors who see this as a little bit of a graveyard or too hard or too early or not going to deliver what it it promises to. And so when you step into a room of skeptics, what I want to hear from you is how do you think about telling them they're wrong. What is your strongest argument that you use that in focus won't end up in that graveyard or, and will actually deliver upon the promise of the science?
00:12:24
Speaker
but it's It's the, the rephrasing, I suppose. um The, the premise is not, not ah us against anybody. It's really as with any emerging um technologies, modalities, ah therapeutic space.
00:12:39
Speaker
the sense is that we are now, um this next cohort, we're standing on the shoulders right of the previous pioneers, trailblazers in the space, the knowledge base that they've built, whether it's in novel modalities in general, RNA targeting. And also um that that's ah that's a big ah theme and in Focus Therapeutics is the AI-driven drug discovery, the tech biospace, and how to bring ah the convergence of these moving forward in the modality and also in the technologies.
00:13:06
Speaker
So the point is that how are we going to come at these questions with a different approach, with a smarter approach, hopefully, and not a brute force, you know, one size fits all method. So more specifically in the RNA targeting, ah we know that first of all, the the the more traditional way to do high throughput screening, to brute force it on with large corporate libraries, to look for binders. That's kind of the The old school thinking for from the protein world, right? That has not proven to be successful in transforming um pro-quality hits in the sense of RNA targeting and transforming to actually draw candidates with with some promise.
00:13:40
Speaker
So we need to ah kind of look beyond that, right? We need to leverage what we know about the RNA biology, we know much more and more about the mechanisms, about the pharmacology, and then to see how we can deploy state-of-the-art technologies like generative technologies, AI, chemoinformatics that we have built up in the protein world to more rationally designed molecules that's giving you the desired pharmacology effect, the disease-modifying outcome that you want that's that's targeting RNA processes.
00:14:13
Speaker
so um And there's another layer on top of that. That's that the integrated um drug discovery development decision-making infrastructure, I like to call it. And because this is something I'm also quite grateful that I'm carrying over from my experience in in the trenches at integrated discovery CROs, because you want to structure decision-making.
00:14:34
Speaker
Because we we really like to talk about technology modules and and silos, but this is a this is a continuum continuum of the process. You need to structure every tactical experiment that you're doing and to bring a compizer closer to the clinic or inflection point to IP value, where you're going to kill it with conviction. So this we we're adapting onto the RNA targeting space as well. And and we consider it to be very important as a strategy.
00:15:01
Speaker
Yeah, I think anytime company is bringing forward a technology that you know is ahead of their peers, it it's going to look challenging, it's going to look difficult. And I think Emily, you bring up a ah great point is that you're rephrasing it.
00:15:16
Speaker
You are standing on the shoulders of what's been done before. Investors are coming with very valid questions about, is this going to work? And there's a lot of reason now in 2025 to think that it it will work because of the specific expertise, especially that InFocus is bringing. So thanks for that answer, Emily.
Global Investor Perspectives
00:15:35
Speaker
i I want to switch gears a little bit again, but but stay along the same lines in communication. you know our Our listeners are interested in communication tactics that help them build strong capital raises. And I i know you're in the midst of that now, but You have a unique experience in speaking to global audiences through all of your BD efforts, particularly in the CRO world.
00:16:00
Speaker
So I'm wondering, you know, we we talk a lot about US investor attitudes, but could you comment on the the different investor attitudes that that you come across in in Europe and China, the global?
00:16:12
Speaker
So think that the the attitudes, the risk appetite, right, particularly, and i find the relationship towards capital and towards entrepreneurship, those are all linked.
00:16:25
Speaker
And in in a lot of these different regions and countries, the role that the healthcare services and businesses and kind of how how this biotech revolution is playing. So, that that all these approaches are quite different. So, it's probably difficult to generalize. And sometimes when people ask me how to how to go to Asia, how to my European colleagues, how to ah to have the US strategy, right? There's no quick recipe. There's no simple answer you're saying. Yeah. And additionally, particularly in the States, you know, it's shifting sand at the Adjust yourself. So um I think for for me, i think that the the most simple ah from my perspective is you have to get out there. it' It's, ah you know, as we were saying the beginning, have to get out on the field.
00:17:07
Speaker
You have to engage. So ah don't don't don't only read on the news, only read the the articles. You have to talk to not only investors, but i Recently, I find it's important to talk to other founders, other partners in the ecosystem, clinicians, payers, regulatory but regulators.
00:17:22
Speaker
think a lot of um early biotechs like myself would probably think that's too early for that, right? I'll worry about it later. But at least my personal approach, I'm trying to get ah in order for you to strategize. And what that means is you have to see a couple steps down the down the line, right? You have to plan.
00:17:38
Speaker
So I speak with ah clinical clinical potential partners to have like a more global view. I think that that helps. I see how all the pieces link together in different different geographies as well.
00:17:54
Speaker
Emily, we often talk about when you're thinking about communicating your vision that you need to always be planning and strategizing with the end goal in mind. And so hearing you say that you think about that now at the very early stages of speaking to clinicians and payers and potential patients, I mean, that to me sounds exactly like that mindset of and end of goal, goal in mind, planning and thinking. So that's, that's really cool that you you see it that way too. I, I feel so many ah like in alignment with you at this point, like we, we think so similarly about so many concepts and I'm always curious when that happens. And I wonder how much of the global background plays into that, but that's a conversation for a different time. So
00:18:38
Speaker
I want to go back to your business development career.
Biotech Leadership vs. Scientist Founders
00:18:41
Speaker
And we always think about leading ah biotech company is selling a vision. And if you've come from BD, you know how to sell. So how do you think...
00:18:55
Speaker
that background and knowing how to sell and talking about vision ah changes the way you approach biotech leadership and and ah specifically compared to the typical scientist founder who hasn't had that sales sort of experience and knows the sales lingo.
00:19:13
Speaker
the the convincing and I think just in a more general way, sales or business development in the bigger sense, where you're trying to in increase and build up um the business, right? In the in the semantic of the of the sense.
00:19:29
Speaker
So I'm more multi-parametric, I think, in my way at the moment to approach biotech entrepreneurship. So um the science is important, the innovation is important, and actually truly, actually dedicate to what that means.
00:19:43
Speaker
But um I think perhaps the contrast with some technical or scientific founders that's really come from that pure science background is I don't tend to have this tendency of brushing off or trivialize some aspects of the company building process, like the administrative part, the business, financial, the relationships, right? That people think, oh, we'll have a partnership strategy later or a team, you know, internally how you're how um my relationship with the team members and the founders, like all of that are, i call them the spinning plates. I'm not saying every single week I can dedicate time to all of these things, but they're not, ah they're concurrent to how I'm, how how I'm conducting this. So I don't, I don't have the assumption to think of, they'll just fall into place later on.
00:20:29
Speaker
um So that's definitely, ah I think a primary, primary difference for me at this stage. Well, on the topic of things that are coming up soon, we'd we'd love to hear what you're excited about in the coming year, Emily, whether you know that relates to InFocus or any trends you see in the bio biopharma space that you're excited about.
Scaling and Partnerships for InFocus
00:20:53
Speaker
So this year, um in the kind in context of Infocus, it's definitely a critical year. So we were um in in in some sense in the incubation phase, right? It's quite remarkable how far we're able to come bootstrapped. Yeah, you've done a lot. We've seen it. Yeah.
00:21:10
Speaker
ah Whether it's building up the technology platform, have a proprietary and silico compound library manage to deliver from from the from those already promising compounds that we put into animal models. So definitely ah the pivotal year where we're kicking off the first seed fundraise right now. So going to the next two quarters, we will um construct a partnership with investors or with companies to scale out what we're able to validate in 2024 and really take it to the to the next level.
00:21:39
Speaker
So how ah hopefully the goal is to um to bring hope. So this is like what the what what Danny was talking about. um For me, it's not only about that I'm already thinking that far into the clinic. is I'm actually bringing it back to kind of the the reason of doing this.
00:21:56
Speaker
And i remember when I come together with my co-founder in the beginning, we talk about we've all been in the biotech industry for over a decade. And we've been in these organizations where we talk about ah patient first. We're talking about unmet needs.
00:22:11
Speaker
And over a very long period of time, they become the buzzwords that you see on the website. And I think we're probably the kind of people on this team that we're actually thinking about this. Like, what does actually mean?
00:22:22
Speaker
How can we... ah with our actions. um Actually, that' that's not something that's just the marketing slogan that we're using, right? that were and But sometimes we're so far from that. When you're maybe 10 years and you're in the technology part, the day-to-day, you you you don't think about this.
00:22:37
Speaker
Since having started doing this, um whether it's people close to to myself, whether it's when I started to engage with patient groups, um you do get that and maybe I'm just sentimental by nature but I get that sense that you are doing something people think at least people are working on this right there's a sense of hope that we're bringing and for the past year that's been imprinted upon me how important that is and I hope not to lose that in the hecticness of the day-to-day things um so it's a little moments like this that's that' important that drives us forward
00:23:13
Speaker
Yeah, i Emily, I have to confess, I am sentimental like that too. and And admittedly, it is challenging to keep that you know the whole reason that we're all in biotech in mind when you get stuck in the day-to-day.
00:23:27
Speaker
um So what a great reminder. And it really does sound like it's going to be ah critical but very exciting year for InFocus. And so we're very excited to to follow along and and see the success that 2025 is going to be Thank you. Thank you so much. And thank you to all of the support. um And yeah, we hope we can do our best.
00:23:46
Speaker
All right, Emily, to wrap up every podcast, we ask one question of all our our
Lessons in Founding and Networking
00:23:53
Speaker
interviewees. And for you, I want you to think back to a year ago when you were just beginning the journey of founding in focus and being a CEO for the first time. And if you could go back and rewind the clock and talk to Emily from a year ago, what's the one piece of advice you would give her so that to avoid a ah mistake or a ah problem that you faced that you wish you had known about beforehand so usually there's a lot of answers here but try and just give us one that's a very difficult i am not the the but whether it's a good sign as a entrepreneur or not i you know this this typical question what would you tell yourself from the past 10 years ago
00:24:35
Speaker
right to To some extent, there's the you know sort of what you would have done differently. At the risk of sounding ah certain way, i don't regret any paths I've taken.
00:24:50
Speaker
Maybe that that's that's the more risk um welcoming risk aspect of myself that led me down this path. I'm definitely with that personality. so i So more specific, what i would I have done something slightly slower so it's a little bit less risky and more conservative?
00:25:05
Speaker
and um Because there's definitely moments where we're maybe waiting for some grant funding or some investor feedback. And are we going to be able to, what do we do next? So we've sort of managed to come come through some challenges.
00:25:19
Speaker
And I know there's still hundreds more to come. um I think just continuing so to surround myself with ah trusted advisors, um people that can support.
00:25:32
Speaker
i actually kind of wish i honestly met you earlier. know and I do mean that because... Because it's been a year and this would have saved me a huge amount of headache probably six months ago.
00:25:45
Speaker
Yeah. That's actually one thing, but I couldn't have control of that. why No, no, that's true. Well, that's that's very kind of you. And, you know, our mission from when we founded the company was to, you know, help people that are starting out and needing that early guidance on messaging and how to tell a strong story. So it's really important.
00:26:07
Speaker
It's really warming to hear that we've had that effect um on you and hopefully others as well. So thank you for sharing that. As far as advice, though, I would say um for, and I have actually other their friends ah due to the current climate, they're ones that's some getting their feet wet and it was starting to consider entrepreneurship.
00:26:26
Speaker
And um I'd say, i'd say ah obviously, the people part. We talk about people, we talk about your founder relationship. And I say this as this is akin to marriage advice. It is, in some sort of a way, um getting into a long-term relationship, right? So expect that it's It's like that. It's not going to be all sunshine and rainbows. going to be rugged. you It's not going to be linear. It's going to be iterative.
00:26:50
Speaker
There's some like you know super happy moments and you're going to come across um discussions. So you have to think about potentially in the next 10 years, five or 10. And not to say you will be together for 10 and things happen, but I think that um the horizon is important.
00:27:07
Speaker
It's people that I want to get into a long-term relationship with. So that I am using as a guideline for how I consider the the human aspect of building an organization.
00:27:20
Speaker
That's so funny because this is the exact conversation Will and I had at the very beginning of starting MightySpark Communications. was like, Will, this is like we're about to get married. ah yeah Are you on board with me for like the next however many years? So we joke about that a lot now in hindsight, but yeah, it's really, really valid advice. Absolutely.
00:27:41
Speaker
So thank you. Thanks so much. Definitely. Emily, thanks so much for joining us. it's been such a pleasure and thanks for sharing your experiences.
Importance of Partnerships and Capital Efficiency
00:27:50
Speaker
Well, what a unique perspective Emily brings.
00:27:52
Speaker
From her own experiences at CRO, she's firsthand experiencing the value true partnership between a biotech or pharma company and a surface provider brings. It's really win-win for both parties and ultimately a really rewarding experience when that partnership, you know, turns out right and goes well. Yeah, I agree, Danny. It's it's definitely a win-win for both parties.
00:28:14
Speaker
I want to think about how they've been so efficient with the capital that they have. And I think part of that has been Emily's decision-making infrastructure, wherein every piece of their R&D advances their candidate closer to the clinic. And Danny, i know, of course, you and I have spent a lot of time in our biotech days making sure the experiments that we were running were tailored right to this goal. So this this really resonated with me.
00:28:36
Speaker
I, for one, appreciated Emily's thoughts around rephrasing a pitch to investors that you know could be falling flat. Whatever preconceived notions someone might have about a particular field, it's best to reframe those thoughts as the lead up to your pitch. Yes, there have been failures in the past, but we're standing on top of those failures with new learnings. And I think that's such an effective tool.
00:28:57
Speaker
Well, first of all, well, don't bring up our former time in biotech where we had to make those experiments perfect. I mean, I still have some very traumatic memories from that time and the stress that we were Yeah, sorry to that to you. Yeah, but in all seriousness, I really, from the moment I met Emily and heard her talk, I knew that we shared a global perspective. And myself having spent time in the US and New Zealand and also being from Australia has really showed me the meaning of getting to know your audience.
00:29:27
Speaker
Because it's so true that when you make that authentic connection with people and have a thorough understanding of them, no matter what their background is, that's really key in aligning a group to a vision and executing upon that vision. And I can personally say that one of the biggest joys I have in leading MSC is getting that opportunity to truly get to know not just the scientific or the corporate story, but the people that make the magic happen.
00:29:55
Speaker
Absolutely. Along those same lines, Danny, another aspect of, you know, knowing your audience and building relationships that Emily spoke to is the respect she has for everyone at the table. And she's made real inroads with that philosophy. And personally, i resonate with that too.
00:30:12
Speaker
So with that, join us next time as we continue this journey to power scientific innovation with storytelling to drive transformative change and solve our most demanding challenges.